Acquired (Autoimmune) Hemolytic Anemia Global Clinical Trials Review, H2, 2018

Published : Oct-2018

No. of Pages : 484

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Acquired (Autoimmune) Hemolytic Anemia to Hematological Disorders Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Acquired (Autoimmune) Hemolytic Anemia to Hematological Disorders Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 30
Subjects Recruited Over a Period of Time 31
Clinical Trials by Sponsor Type 32
Prominent Sponsors 33
Top Companies Participating in Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials 35
Prominent Drugs 37
Clinical Trial Profile Snapshots 39
Appendix 482
Abbreviations 482
Definitions 482
Research Methodology 483
Secondary Research 483
About GlobalData 483
Contact Us 484
Source 484

List of Tables
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials by Region, 2018* 7
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Acquired (Autoimmune) Hemolytic Anemia to Hematological Disorders Clinical Trials, G7 Countries (%), 2018* 17
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Acquired (Autoimmune) Hemolytic Anemia to Hematological Disorders Clinical Trials, E7 Countries (%), 2018* 22
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials by Phase, 2018* 26
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

List of Figures
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Acquired (Autoimmune) Hemolytic Anemia to Hematological Disorders Clinical Trials, G7 Countries (%), 2018* 16
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Acquired (Autoimmune) Hemolytic Anemia to Hematological Disorders Clinical Trials, E7 Countries (%), 2018* 21
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27
Acquired (Autoimmune) Hemolytic Anemia Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Acquired (Autoimmune) Hemolytic Anemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37
GlobalData Methodology 483

Filed in: In Vitro Diagnostic, Medical Device

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026 “The global in vitro fertilization market size is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1 % during the forecast period” The global in vitro fertilization market is projected to reach USD 987 million by 2026 from USD 638 million in 2021, at a CAGR of 9.1% from 2021 to 2026. The key factors fueling the growth of this market include an increase in the median age of first-time mothers, declining fertility rates, rising male infertility, rise in obesity rate and growing consumption of alcohol, and growing awareness about the availability of treatment options. However, the high cost and low success rate of IVF treatment and restrictive regulations and ethical concerns are expected to restrict the growth of the IVF market to a certain e......	$4950
Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact) Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) Summary Assisted Reproductive Technology Devices (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within General Surgery therapeutic area. The model discusses in detail the impact of COVID-19 on Assisted Reproductive Technology Devices market for the year 2020 and beyond. Assisted Reproductive Technology (ART) refers to reproductive health procedures that treat infertile women to achieve pregnancy. For decades now across much of the developed world, several techniques of ART have been in use with varying pregnancy success rates. These techniques primarily include, but are no......	$7500
Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact) Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) Summary Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) - Global Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on Multiparameter CT/NG NAAT Tests market for the year 2020 and beyond. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia Trachomatis. In women, Chlamydia Trachomatis infections are often asymptomatic, however, if left untreated they can cause pelvic inflammatory disease (PID), which in turn can lead to additional complications such as infertility, ectopic preg......	$7500
Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028 Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028 Summary Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively. Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood. Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care. Although these therapies are effective, they are associated with a great treatment burden. There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing a......	$10995
Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Human Immunodeficiency Virus (HIV) has become one of the world's most serious health issues affecting approximately 36.9 million people. The epidemiology of HIV infections varies from one geographical region to another. Sources indicate that in many countries, incidence rates for HIV have stabilized due to the campaigns that provide condoms, pre-exposure prophylaxis, sterile needles, syringes, antiretroviral therapy (ART), and prevention of mother-to-child transmission interv......	$7500
Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary Chlamydia Trachomatis Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Chlamydia is a common sexually transmissible disease, caused by the bacteria Chlamydia trachomatis. Patient access to Chlamydia screening, and thus the number of reported cases, varies substantially between countries. In some countries annual screening is recommended for specific patient groups deemed to be at higher risk of contracting the disease, such as sexually active females younger than 25 years. Additionally, screening of pregnant women for Chlamydia Trachomatis infections is currently recomme......	$7500
EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model Summary EGFR Tests (In Vitro Diagnostic) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. There are two main types of lung cancer; small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC accounting for approximately 80-90% of all lung cancer cases. The 5-year survival rate for patients with stage IV disease is less than 5% as majority of patients present with the advanced or metastatic disease at diagnosis. EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating ......	$7500
Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated Human Papilloma Virus (HPV) tests into their cervical cancer and pre-cancer screening programs. Cytology based screening programs require a well-established healthcare infrastructure for processing and interpretation of samples. It is hoped that HPV screening methods may enable better prevention of these disease, these devices are also highly sensitive an......	$7500
Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model "Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Cytomegalovirus (CMV) represents the most common congenital, viral infection in the developed world and awareness of this disease is increasing. Few countries have official guidelines in place for CMV screening but in general testing tends to be performed for sperm donations, immunocompromised cases, and pregnant women. Diagnosis of CMV infections is complex as symptoms are often non-specific and mimic mononucleosis or the flu. Approximately 21-25% of primary CMV infections are symptomatic ......	$7500
Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model Summary Prenatal Screening (In Vitro Diagnostics) - Global Market Analysis and Forecast Model is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area. Prenatal Screening is now routinely used in developed countries for early detection of fetal abnormalities. Various biochemical analytes are measured during the first or second trimester including free-beta human chorionic gonadotropin (hCG), total hCG, pregnancy associated plasma protein-A (PAPP-A), Alpha-fetoprotein (AFP), unconjugated estriol (uE3), and Inhibin A. These markers are used to screen for Down syndrome (Trisomy 21) as well as Edwards syndrome (Trisomy 18) and ectopic pregnancy. Additionally, maternal s......	$7500

Acquired (Autoimmune) Hemolytic Anemia Global Clinical Trials Review, H2, 2018

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

In Vitro Fertilization /IVF Market by Product (Micromanipulators, Incubators, Cabinets, Imaging System, Laser System, Reagents & Accessories), Type (Conventional IVF, IVF with ICSI), End User (Fertility Clinics, Hospitals, Cryobanks) – Global Forecast to 2026

Assisted Reproductive Technology Devices (General Surgery) – Global Market Analysis and Forecast Model (COVID-19 market impact)

Multiparameter CT/NG NAAT Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Hemophilia A and B – Global Drug Forecast and Market Analysis to 2028

Human Immunodeficiency Virus (HIV) Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Chlamydia Trachomatis Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

EGFR Tests (In Vitro Diagnostic) – Global Market Analysis and Forecast Model

Human Papilloma Virus (HPV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Cytomegalovirus (CMV) Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model

Prenatal Screening (In Vitro Diagnostics) – Global Market Analysis and Forecast Model